Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS.

Sriram S, Yao SY, Stratton C, Moses H, Narayana PA, Wolinsky JS.

J Neurol Sci. 2005 Jul 15;234(1-2):87-91.

PMID:
15935383
3.

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, Andersen O, Christensen T, Ekholm S, Haahr S, Höllsberg P, Bergström T, Svennerholm B, Jakobsen J.

Neurology. 2002 Jan 8;58(1):31-6.

PMID:
11781402
4.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
5.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
6.

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

Brod SA, Lindsey JW, Vriesendorp FS, Ahn C, Henninger E, Narayana PA, Wolinsky JS.

Neurology. 2001 Sep 11;57(5):845-52.

PMID:
11552015
7.
8.

Pilot study of minocycline in relapsing-remitting multiple sclerosis.

Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG, Mitchell JR.

Can J Neurol Sci. 2008 May;35(2):185-91.

PMID:
18574932
9.

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.

Then Bergh F, Kümpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismüller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP.

BMC Neurol. 2006 May 23;6:19.

10.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.

Neurology. 2006 Sep 26;67(6):944-53.

PMID:
17000959
11.

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.

Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group.

Brain. 2001 Sep;124(Pt 9):1803-12.

PMID:
11522582
12.

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.

Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.

Neurology. 2008 Oct 28;71(18):1390-5. doi: 10.1212/01.wnl.0000319698.40024.1c. Epub 2008 Jun 4.

PMID:
18525027
13.

Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.

Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.

Mult Scler. 2008 May;14(4):479-84. doi: 10.1177/1352458507085555.

PMID:
18562504
14.

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in Relapsing MS Study Group.

Neurology. 2005 Mar 22;64(6):987-91.

PMID:
15781813
15.

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.

Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.

Arch Neurol. 2008 Feb;65(2):199-204. Epub 2007 Dec 10.

PMID:
18071030
16.

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators.

Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21.

PMID:
18208877
17.

A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.

Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D, Katsamakis G, Feinstein DL.

J Neuroimmunol. 2009 Jun 25;211(1-2):124-30. doi: 10.1016/j.jneuroim.2009.04.011. Epub 2009 May 15.

PMID:
19446890
18.

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.

Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E, Weiss S, Shifroni G, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group.

Mult Scler. 2007 May;13(4):502-8. Epub 2007 Feb 9.

PMID:
17483532
19.

Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.

Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):407-14. Epub 2007 Jun 5.

PMID:
17550987
20.

Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.

Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.

Mult Scler. 2007 May;13(4):490-501. Epub 2007 Feb 9.

PMID:
17463072

Supplemental Content

Support Center